Medical News

RSS

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

Sugar in excess leads to complications

In light of Diabetes Awareness Month, many people are showing increased interest in the topic of sugar and sugar alternatives. With the various forms of sugar available table sugar, high-fructose corn syrup, agave, and honey understanding the differences between sugars and their effects on the body is not all sweet.

1 Nov 2010

American Psychological Association blocking therapists from learning effective treatments for PTSD

In the wake of enormous controversy about its role in the participation of psychologists in the use of torture to extract information from prisoners at Guantanamo Bay and in other parts of the world, an interview just carried by Truthout reveals a new round of criticism that has been directed toward the American Psychological Association (APA).

1 Nov 2010

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Oncimmune® LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, today announced that two oral presentations and five poster presentations during this week's American College of Chest Physicians' (ACCP) annual meeting in Vancouver will collectively highlight the clinical and economic benefits of EarlyCDT-Lung.

1 Nov 2010

AXIOM releases HIPAA 5010 compliant version of TransSend

AXIOM Systems, Inc., today announced the general release of its HIPAA 5010 compliant version of TransSend, a software application developed specifically for healthcare organizations engaged in HIPAA EDI commerce.

1 Nov 2010

Compli announces strategic alliance with Wallace Welch & Willingham

Compli, the nation's leading provider of HR and compliance management software, is proud to announce a strategic alliance with Wallace Welch & Willingham, a leading privately held insurance agency with more than 85 years of experience.

1 Nov 2010

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Researchers are calling for clear guidelines on childhood stroke after a study, published in the November issue of Acta Paediatrica, found wide variations in time lag to diagnosis, investigation and treatment.

1 Nov 2010

Integra LifeSciences signs multi-year contract with The Broadlane Group

Integra LifeSciences Holdings Corporation announced today that it has signed a multi-year contract with The Broadlane Group to provide dural repair, neuro trauma (neuro critical care), and hydrocephalus products and accessories to its client hospitals.

1 Nov 2010

Diabetes Research Institute kicks off 'Be Part of the CURE' online campaign

Beginning today, thousands of people who want to help put an end to diabetes can be part of the cure by participating in the Diabetes Research Institute Foundation's online campaign at BePartoftheCure.org. Kicking off National Diabetes Awareness Month, the Be Part of the CURE campaign is a fun and meaningful way for people living with diabetes, their family and friends, and anyone concerned about curing this devastating disease to literally participate in the "CURE."

1 Nov 2010

GE Healthcare enters agreement to acquire assets of Orbotech Medical

GE Healthcare, a unit of General Electric Company announced that it has entered into an agreement to acquire the assets of Orbotech Medical Solutions Ltd., a subsidiary of Orbotech Ltd. (Orbotech), and a manufacturer of cadmium zinc telluride (CZT) detectors used in GE Healthcare's innovative Alcyone nuclear medicine technology.

1 Nov 2010

Understanding flirting key to positive romantic interactions

A little self-awareness can help people struggling in the world of relationships, says Jeffrey Hall, assistant professor of communication studies at the University of Kansas.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Dyadem opens second office to meet customer demand for enterprise risk management software

Dyadem today announced the opening of its second office in Europe; located in Starnberg, Germany, on the outskirts of Munich. Dyadem, the leader in Operational and Quality Risk Management, has expanded in response to a surge in customer demand in the European Union for its enterprise risk management software and services amid heightened scrutiny of safety and quality standards for companies in the oil & gas, chemical, medical device and pharmaceutical industries.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

An overwhelming majority of Breast Cancer Surveillance Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) in the U.S. are up-to-par with American College of Radiology Imaging Network (ACRIN) and European Society of Breast Imaging (EUSOBI) technical standards and requirements, according to a study in the November issue of the Journal of the American College of Radiology.

1 Nov 2010

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

Intentional foreign body ingestion results in over $2 million hospital costs: Study

A new study from Rhode Island Hospital found that 33 individuals were responsible for 305 cases of medical intervention to remove foreign bodies that were intentionally swallowed, resulting in more than $2 million in estimated hospital costs. The findings appear in the November issue of Clinical Gastroenterology and Hepatology.

1 Nov 2010

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.

1 Nov 2010

Medical News

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

Sugar in excess leads to complications

American Psychological Association blocking therapists from learning effective treatments for PTSD

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

AXIOM releases HIPAA 5010 compliant version of TransSend

Compli announces strategic alliance with Wallace Welch & Willingham

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Integra LifeSciences signs multi-year contract with The Broadlane Group

Diabetes Research Institute kicks off 'Be Part of the CURE' online campaign

GE Healthcare enters agreement to acquire assets of Orbotech Medical

Understanding flirting key to positive romantic interactions

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Dyadem opens second office to meet customer demand for enterprise risk management software

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Mechanism of rogue cell killer discovered

Intentional foreign body ingestion results in over $2 million hospital costs: Study

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News